Anti-Fibrinolytic Drugs - Australia

In Australia, the revenue in the Anti-Fibrinolytic Drugs market is estimated to reach US$164.90m in 2024.
It is anticipated that there will be a steady annual growth rate (CAGR 2024-2029) of 4.92%, leading to a market volume of US$209.70m by 2029.
When compared globally, United States is expected to generate the highest revenue, amounting to US$9.86bn in 2024.
Australia has seen a significant increase in the demand for anti-fibrinolytic drugs, driven by an aging population and a rise in surgical procedures.

Definition:
The Anti-Fibrinolytics market covers drugs which help blood to clot. They are used to treat and prevent bleeding episodes of patients with hemophilia. Moreover, anti-fibrinolytics are used before or during certain surgeries. In doing so, the usage of blood products, such as fresh frozen plasma, as well as the associated risks of infections and/or anaphylactic reactions can be avoided.

Additional information:
Market values represent the revenues generated by manufacture prices paid to primary vendors, either directly or through distribution channels (excluding VAT). Reported market revenues include spending by consumers (B2C), companies (B2B), and governments (B2G).

Company examples: Roche, Takeda, Novo Nordisc, Sanofi, Bayer

Inhibitors of fibrinolysis
Drugs to treat hemophilia

Anti-coagulants
Anti-hypertensives
Wound care

The Anti-Fibrinolytic Drugs market in Australia has been experiencing growth in recent years.

Customer preferences: The demand for Anti-Fibrinolytic Drugs in Australia is driven by the increasing prevalence of bleeding disorders, such as hemophilia and von Willebrand disease. Patients with these conditions require regular treatment with clotting factors to prevent bleeding episodes and manage their symptoms. Additionally, there is a growing awareness among healthcare professionals and patients about the benefits of Anti-Fibrinolytic Drugs in managing bleeding disorders.

Trends in the market: One of the key trends in the Anti-Fibrinolytic Drugs market in Australia is the increasing use of newer drugs, such as tranexamic acid and aminocaproic acid. These drugs have been shown to be more effective and have fewer side effects than older drugs like epsilon-aminocaproic acid. Another trend is the growing use of prophylactic treatment in patients with bleeding disorders, which involves the regular administration of clotting factors to prevent bleeding episodes.

Local special circumstances: Australia has a well-established healthcare system that provides universal access to healthcare services. This has helped to ensure that patients with bleeding disorders have access to the treatments they need, including Anti-Fibrinolytic Drugs. Additionally, there is a strong focus on research and development in the healthcare sector, which has led to the development of new and more effective treatments for bleeding disorders.

Underlying macroeconomic factors: The growth of the Anti-Fibrinolytic Drugs market in Australia is supported by several macroeconomic factors. These include a growing aging population, which is more susceptible to bleeding disorders, and an increasing prevalence of chronic diseases such as diabetes and cardiovascular disease, which can also increase the risk of bleeding. Additionally, there is a growing demand for healthcare services in Australia, which has led to increased investment in the healthcare sector and the development of new treatments for bleeding disorders.

Data coverage:

Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.

Modeling approach / Market size:

Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.

Forecasts:

In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.

Additional notes:

Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.

This report presents a comprehensive analysis and additional information on the Health market, in a PDF format.

Bleeding disorders affect the clotting of blood and can result in excessive bleeding inside and outside of the body. Bleeding disorders are almost always inherited and common symptoms include easy bruising, frequent nosebleeds, heavy menstrual bleeding, and excessive bleeding from small cuts. Treatments vary depending on the type of disorder, but may include factor replacement therapy, iron supplementation, topical products or sprays, or blood transfusions. The most common types of bleeding disorders are hemophilia A and B and von Willebrand disease. In 2022, there were around 257,146 people worldwide who had been diagnosed with hemophilia and 100,505 who had been diagnosed with von Willebrand disease.